Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient

Status Completed

Clinical Trial Summary

Modulation of beta-amyloid levels in CSF and plasma by GSK933776 in patients with mild Alzheimer's disease or mild cognitive impairment

Clinical Trial Description

This is a phase I, an open label, single dose and parallel group study to assess short term pharmacodynamics and safety of GSK933776. The effect on the beta amyloid levels will be assessed in early (MCI) and mild Alzheimer's disease (AD) patients after a single dose of GSK933776 by i.v. administration. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01424436
Study type	Interventional
Source	GlaxoSmithKline
Contact
Status	Completed
Phase	Phase 1
Start date	May 19, 2010
Completion date	December 8, 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05040048` - Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
Withdrawn	`NCT03316898` - A FDG-PET Study of AGN-242071 Added to Standard-of-Care (Donepezil ± Memantine) for the Treatment of Participants With Mild to Moderate Alzheimer's Disease	Phase 1
Withdrawn	`NCT02860065` - CPC-201 Alzheimer's Disease Type Dementia: PET Study	Phase 2
Completed	`NCT01315639` - New Biomarker for Alzheimer's Disease Diagnostic	N/A
Not yet recruiting	`NCT03740178` - Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)	Phase 1
Recruiting	`NCT05607615` - A 6-Month Study to Evaluate the Safety & Potential Efficacy of Trappsol Cyclo in Patients With Early Alzheimer's Disease	Phase 2
Terminated	`NCT03307993` - Positron Emission Tomography (PET) Study in Patients With Alzheimer's Disease	Phase 1
Recruiting	`NCT02912936` - A Medium Chain Triglyceride Intervention for Patients With Alzheimer Disease	N/A
Active, not recruiting	`NCT02899091` - Evaluation of the Safety and Potential Therapeutic Effects of CB-AC-02 in Patients With Alzheimer's Disease	Phase 1/Phase 2
Completed	`NCT02907567` - Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease	Phase 1/Phase 2
Not yet recruiting	`NCT02868905` - Identification of Epigenetic Markers Common to Obesity and Alzheimer's Disease in Women	N/A
Terminated	`NCT02521558` - Effectiveness of Home-based Electronic Cognitive Therapy in Alzheimer's Disease	N/A
Completed	`NCT02516046` - 18F-AV-1451 Autopsy Study	Phase 3
Completed	`NCT02580305` - SUVN-502 With Donepezil and Memantine for the Treatment of Moderate Alzheimer's Disease- Phase 2a Study	Phase 2
Recruiting	`NCT02247180` - Cognitive Rehabilitation in Alzheimer`s Disease	N/A
Completed	`NCT02260167` - Treatment of Alzheimer's and Dementia With the Metabolism, Infections, Nutrition, Drug Elimination (MIND) Protocol	N/A
Completed	`NCT02256306` - The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study	N/A
Completed	`NCT02317523` - Alzheimer's Caregiver Coping: Mental and Physical Health	N/A
Terminated	`NCT02220738` - Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors	Phase 1
Completed	`NCT01920672` - Disrupted Sleep, Neuroendocrine Status and the Behavioral Symptoms of AD	N/A